Convalescent Plasma News and Research

RSS

Mapping antibody reactivity in COVID-19 patients by using multi-coronavirus protein microarray

In an exciting, state-of-the-art study currently available on the medRxiv* preprint server, US researchers created a multi-coronavirus protein microarray containing full-length proteins, peptide libraries, and overlapping protein fragments from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as four other human coronaviruses.

19 Jan 2021

Study predicts good passive immunotherapy donors to combat COVID-19

A US-based research team determine good candidates for convalescent plasma donations in promoting passive immunity among severely-ill COVID-19 patients.

19 Jan 2021

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

An interesting new preprint published on the medRxiv server describes an immunosuppressed patient with coronavirus disease 2019 (COVID-19) who continued to shed the virus for an astounding 154 days. During this period, the virus underwent numerous mutations.

19 Jan 2021

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

A new study suggests that modified natural killer cells, which express a chimeric antigen receptor using S309 antibody, can bind to and inactivate SARS-CoV-2 spike protein in vitro.

18 Jan 2021

Could Ivermectin be an effective antiviral against SARS-CoV-2?

A double-blind, randomized, placebo-controlled clinical trial has recently demonstrated that Ivermectin, an anti-parasitic drug, can reduce in-hospital mortality rate of COVID-19 patients.

11 Jan 2021

Synthetic lung organoids provide high-throughput platform to identify new cellular targets of SARS-CoV-2

An interesting new study published on the bioRxiv preprint server describes a new platform that allows a high-throughput workflow to generate matched human lung buds in the tens of thousands. This allows researchers to study SARS-CoV-2 infection and therapeutics in lung tissue that mirrors the key aspects of human lung development.

10 Jan 2021

Single-dose nanoparticle COVID-19 vaccine elicits virus-neutralizing antibody response in mice

Across the world, health care workers and high-risk groups are beginning to receive COVID-19 vaccines, offering hope for a return to normalcy amidst the pandemic.

8 Jan 2021

How do SARS-CoV-2 antibodies change over time in recovered patients?

Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.

8 Jan 2021

SARS-CoV-2 viral load in saliva may be linked to COVID-19 disease severity

Researchers at Yale University School of Medicine found that SARS-CoV-2 viral loads in saliva are higher for patients with associated risk factors and underlying conditions that lead to severe COVID-19 and death. Thus, saliva viral loads could be used to predict disease severity.

7 Jan 2021

Anti-SARS-CoV-2 NTD-directed antibodies are protective against lethal infection

As the world struggles to contain the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for over 1.6 million deaths and 76 million infections globally, researchers are trying to pin down the determinants of lethality, of infectivity and of protection. Such data would help contain its spread and develop preventive and therapeutic antivirals and vaccines. A new preprint that appeared recently on the bioRxiv* server describes the high degree of protection afforded by antibodies that target the N-terminal domain (NTD) of the virus.

24 Dec 2020

Cross-reactive coronavirus antibodies shape COVID-19 convalescent plasma functionality

The onset of the current COVID-19 pandemic revealed the seventh known pathogenic human coronavirus, SARS-CoV-2.

21 Dec 2020

Rapid point-of-care lateral flow assay to assess the neutralizing activity of plasma against SARS-CoV-2

A new paper describes the development and validation of a rapid test to measure the neutralizing activity of serum against COVID-19 using a drop of blood.

18 Dec 2020

Abbott gets CE Mark for new quantitative SARS-CoV-2 IgG lab-based serology test

Abbott announced today it received CE Mark for its new quantitative SARS-CoV-2 IgG (Immunoglobulin G) lab-based serology test.

18 Dec 2020

Azithromycin trial fails to provide evidence of benefit in COVID-19

Early on in the COVID-19 pandemic, azithromycin was regarded as being a potentially highly effective drug against the virus that causes it, SARS-CoV-2.

16 Dec 2020

Remdesivir likely to be highly effective treatment for COVID-19

The drug remdesivir is likely to be a highly effective antiviral against SARS-CoV-2, according to a new study by a team of UK scientists.

14 Dec 2020

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

The focus is increasingly moving towards vaccine roll-out as the world faces the real possibility of the second year of social and economic restrictions.

14 Dec 2020

Repurposed mouse model sheds light on spectrum of COVID-19 disease symptoms

A repurposed mouse model can develop symptoms of both severe COVID-19 (lung damage, blood clots, abnormal blood vessels, and death) and also of milder disease, including loss of the sense of smell, according to a recent University of Iowa study published in Nature.

1 Dec 2020

Chinese woman still sheds SARS-CoV-2 over four months post-infection

A new study by Chinese scientists explore an unusual case of extended viral shedding in a 68-year-old woman up to four months post-infection.

1 Dec 2020

Convalescent plasma therapy ineffective in treating severe COVID-19, study finds

A recent study based at a hospital in Buenos Aires, Argentina, found that convalescent plasma therapy for patients with severe COVID-19, and COVID-19-related pneumonia, was largely ineffective.

25 Nov 2020

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

A new study released on the medRxiv* preprint server indicates that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic – is developing multiple mutations that affect neutralization by antibodies.

24 Nov 2020

Convalescent Plasma News and Research

Mapping antibody reactivity in COVID-19 patients by using multi-coronavirus protein microarray

Study predicts good passive immunotherapy donors to combat COVID-19

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

Could Ivermectin be an effective antiviral against SARS-CoV-2?

Synthetic lung organoids provide high-throughput platform to identify new cellular targets of SARS-CoV-2

Single-dose nanoparticle COVID-19 vaccine elicits virus-neutralizing antibody response in mice

How do SARS-CoV-2 antibodies change over time in recovered patients?

SARS-CoV-2 viral load in saliva may be linked to COVID-19 disease severity

Anti-SARS-CoV-2 NTD-directed antibodies are protective against lethal infection

Cross-reactive coronavirus antibodies shape COVID-19 convalescent plasma functionality

Rapid point-of-care lateral flow assay to assess the neutralizing activity of plasma against SARS-CoV-2

Abbott gets CE Mark for new quantitative SARS-CoV-2 IgG lab-based serology test

Azithromycin trial fails to provide evidence of benefit in COVID-19

Remdesivir likely to be highly effective treatment for COVID-19

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

Repurposed mouse model sheds light on spectrum of COVID-19 disease symptoms

Chinese woman still sheds SARS-CoV-2 over four months post-infection

Convalescent plasma therapy ineffective in treating severe COVID-19, study finds

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News